NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization450.36 mln
Float55.95 mln
Earnings Date07/30/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-0.68
Highly suspicious
1-Year Forecast
15.00
Transformational upside
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-41.69
Deeply negative
Business Description
Arvinas is a New Haven-based biotechnology company focused on developing drugs that eliminate harmful proteins linked to serious diseases. Rather than blocking these proteins, its treatments are designed to remove them from the body entirely using a mechanism the body already employs naturally. The company has several experimental drugs in development targeting conditions such as prostate cancer, breast cancer, certain blood cancers, pancreatic cancer, and Parkinson's disease. Arvinas works alongside major pharmaceutical partners including Pfizer, Roche, and Bayer to advance its research pipeline.
